All of 520 enrolled subjects from PI-88’s phase III clinical trial has completed their course of treatments by January 26, 2015.
The trial was originally designed for another 2 years of follow up after course of treatment, the board of directors has
decided to early conclude the trial with the implementation of Study Conclusion Plan. Once the data collection and
statistical analysis are completed, this clinical study report will be submitted to TFDA for review. Medigen Biotech Co.
will determine future development plan for PI-88 based on results of statistical analysis and recommendations from authorities such as TFDA.